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INTRODUCTION
Pheochromocytoma is a rare disorder and functioning tumor
composed of chromaffin cell that secrete catecholamines,
affecting one in a million people per year. Eighty-five per-
cent are found in the medullae of the adrenal glands, but
they may also occur in the extra-adrenal, paraganglia. Patients
with a pheochromocytoma ‘crisis’ have high mortality, mostly
from a cardiovascular origin, in spite of aggressive therapy.
We present an unusual case of a severe acute catecholamine
cardiomyopathy presenting ST segment elevation with car-
diogenic shock after hemorrhage into a left adrenal tumor.
Medically unresponsive shock was successfully treated with
multiple invasive strategies.  
CASE REPORT
A 43-yr-old man presented with acute severe chest pain,
shortness of breath, and dyspnea. Three year before, he had
an episodic hypertensive crisis with chest discomfort and was
diagnosed with pheochromocytoma. He had already severe
left ventricular (LV) dysfunction (ejection fraction 27%, end-
diastolic/end-systolic dimension 59/48 mm) due to suspi-
cious catecholamine-induced cardiomyopathy. He was rec-
ommended to receive operation for the tumor but refused
appropriate treatment without follow-up. He did not smoke
and had no other risk factors for coronary artery disease. Phys-
ical examination revealed an ill, sweaty patient, with a blood
pressure of 194/115 mmHg and a heart rate of 117 bpm.
Initial cardiopulmonary examination revealed elevated jugu-
lar venous engorgement, and chest radiography showed signs
of pulmonary edema. Echocardiography (ECG) showed sinus
tachycardia, rate of 110 bpm, and significant ST depressions
in II, III, AVF, V4-6 (Fig. 1A). He was treated with aspirin,
intravenous (IV) nitrate, and heparin. Several minutes later,
suddenly, he developed loss of consciousness with supraven-
tricular tachycardia on repeated ECG, coinciding with extreme
hypotension (71/undeterminable mmHg). DC cardioversion
and tracheal intubation was performed immediately. Blood
pressure did not restored after cardioversion with aggressive
intravenous fluid therapy and ECG turned into ST elevation
with tachycardia in the precordial leads (Fig. 1B). Cardiac
enzyme showed myocardial damage; creatine kinase (CK) 667
IU/L (normal <250), CK-MB 34.6 ng/mL (normal <5), and
myoglobin 1,462 ng/mL (normal <110) (Fig. 2). Echocardiog-
raphy showed global hypokinesia, especially more hypoki-
netic in anterior and antero-septal wall in left ventricle (LV).
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Catastrophic Catecholamine-Induced Cardiomyopathy Mimicking Acute
Myocardial Infarction, Rescued by Extracorporeal Membrane
Oxygenation (ECMO) in Pheochromocytoma
Pheochromocytoma is a rare disorder and functioning tumor composed of chromaf-
fin cells that secrete catecholamines. Patients with a pheochromocytoma ‘crisis’
have a high mortality in spite of aggressive therapy. We present a case with a severe
acute catecholamine cardiomyopathy presenting ST segment elevation with car-
diogenic shock after hemorrhage into a left suprarenal tumor. Intra-aortic balloon
pump (IABP) support, combined with inotropic therapy, was performed. However,
the patient deteriorated rapidly and was unresponsive to a full dose of inotropics
and IABP. We decided to apply extracorporeal membrane oxygenation (ECMO)
device for the patient. His clinical state began to improve 3 days after ECMO. After
achieving hemodynamic stabilization, he underwent successful laparoscopic left
adrenalectomy. He needed no further cardiac medication after discharge.
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The left ventricular ejection fraction was markedly decreased
less than 35% with increased wall thickness (interventricu-
lar septal wall/posterior wall thickness 16/15 mm). Under
the tentative diagnosis of acute myocandial infarction (AMI),
emergent coronary angiogram was performed despite of known
pheochromocytoma. Coronary angiographic finding is nor-
mal (Fig. 3) and an intra-aortic balloon pump (IABP) was
immediately inserted for hemodynamic support. He was
admitted to the coronary care unit (CCU), and mechanical
ventilation and inotropic agents were started (20  g/kg/min
dobutamine and 20  g/kg/min dopamine). The urinary cat-
echolamine levels were: norepinephrine 3,962  g/day (nor-
mal 30-120), epinephrine 3,044  g/day (normal 2-14), and
vanilmandelic acid (VMA) 88.2 mg/day (normal <8). We
considered the patient’s presentation as acute decompensa-
tion on chronic catecholamine-induced cardiomyopathy.
We decided to support the patient with extracorporeal
membrane oxygenation (ECMO) because hypotension con-
tinued despite of fluid therapy, IV inotropics, and IABP.
Femoral cannulation was done and assess was achieved with
a percutaneous, guidewire-based technique. During ECMO,
we monitored mean arterial pressure, urine output, blood
lactate concentration, and central or venous mixed venous
oxygen saturation in order to maintain adequate blood flow
Fig. 1. (A) Initial ECG at emergency room showed left ventricular
hypertrophy and ST depression in precordial leads. (B) Follow-up
ECG showed ST elevation when abrupt hypotension occurred.
A
B
Fig. 3. Coronary angiography shows near-normal coronary artery. (A) Right coronary artery and (B) Left coronary arteries.
A B
Fig. 2. The trend of cardiac enzymes.
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and oxygen saturation. To maximized oxygen-carrying capac-
ity, packed red blood cells (RBCs) were transfused to achieve
a hematocrit above 35% and mean arterial blood pressure
was maintained between 60 and 70 mm Hg. Heparin was
administrated continuously to maintain activated clotting
time between 150 and 200 sec to prevent blood clotting of
the ECMO circuit.
On Day 3, all inotropic support could begin to be progres-
sively weaned, with a normal blood pressure and cardiac out-
put. ECMO continued for 3 days maintaining cardiac output
(CO) more than 3.0 L/min. Successful weaning was performed
according to follow-up echocardiographic data suggestive of
improve LV contractility. The IABP was removed 12 hr after
the discontinuation of ECMO. There were no cannulation-relat-
ed complications and major bleedings when ECMO system
removed. Mechanical ventilation was required for a total of
5 days (Fig. 4).
A repeated echocardiographic examination performed by
the same physician 5 days after admission to CCU revealed a
vigorous ventricular contraction with normal LV systolic func-
tion (EF 66%, end-diastolic/end-systolic dimension 49/35
mm). Furthermore, laboratory findings and ECG abnormal-
ity had completely resolved.
Abdominal computerized tomography (CT) confirmed the
presence of a left suprarenal mass of 4 cm, with a central hypo-
dense region suggestive of necrosis and it was no interval change
compared with previous CT (3 yr before) (Fig. 5). After 8 weeks
of therapy with alpha and beta blockers (doxazocin 4 mg bid
and carvediol 12.5 mg qd, respectively), the patient was sent
to elective laparoscopic left adrenalectomy where an about
4.2×3.5×3 cm tumor was removed, which was proven to
be pheochromocytoma (Fig. 6). The patient was discharged
uneventfully without cardiac medication seven days after
surgery. A follow-up ECG obtained 3 months after the first
one showed complete resolution of the ST segment and T
inversion (Fig. 7).
DISCUSSION
Pheochromocytomas are rare neoplasms of chromaffin tis-
Fig. 5. (A) Abdominal computed tomography (CT) scan shows mul-
tiple sepated and well-encapsulated mass with intratumoral hem-
orrhage. (B) Three years later CT showed an enhanced 4.2×3.5
×3 cm sized mass with septated central necrosis (comparison be-
tween 2002 and 2005, arrows indicate tumors).
A B
2002 2005
Fig. 6. Left adrenal gland is a lump of soft mass (4.2×3.5×3 cm)
with weight 28 gm. The cut surface of the mass is yellowish tan and
soft with central hemorrhagic and necrotic areas.
Fig. 7. ECG after removal of tumor showed left ventricular hyper-
trophy without ST change.
Fig. 4. The graph shows the typical hemodynamic pattern of an acute
cardiac events: a low SBP with the need for aggressive inotropic
support and with good response to inotrophic agents. IABP and
ECMO support and fluid therapy restored cardiac output during
the first three days. Continuous cardiogenic shock was treated with
dobutamine and norepinephrine temporarily. Continuous inotropic
agents were discontinued at day 5. 
IABP, intra-aortic balloon pump, ECMO, extracorporeal membrane
oxygenation, SBP, systolic blood pressure.
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sue derived from the embryonic neural crest and produce their
distant effects by secretion of excessive amount of catechol-
amines (1). The classic, clinical presentations of pheochromo-
cytoma, such as headache, sweating attacks, tachycardia, and
hypertension are highly sensitive and specific, but not always
present (2). In addition to the classic symptoms, pheochro-
mocytomas have been rarely presented with acute myocardi-
tis, AMI, cardiomyopathy, or hemodynamic collapse (3).
Catecholamine-induced cardiomyopathy has acute or chron-
ic clinical forms. Acute form is associated with an excessive
catecholamine surge and prone to present as acute cardiac fail-
ure, including acute pulmonary edema or cardiogenic shock
(3). Especially with heart failure, patients may have very gloomy
prognosis because of extensive myocardial damage (4). Chron-
ic forms are manifested as dilated cardiomyopathy or hyper-
trophic cardiomyopathy with or without outflow tract obstruc-
tion, leading to congestive heart failure (3, 5).
Clinical reports describing the pheochromocytoma-induced
MI are rare (6). When it occurs, ECG can show ST elevation
or, more commonly, non-ST elevation MI. It is not unusual
for the patient with pheochromocytoma-related MI to present
with acute, severe symptoms leading rapidly to death and
diagnosis made at autopsy. Most of patients in these cases had
no significant coronary atherosclerosis in contrast to classic
MI (7). High levels of catecholamine released by the tumor
can increase myocardium metabolism and cause coronary
vasospasm resulting in angina, MI, and cardiomyopathy,
which could be irreversible if left untreated (8-10).
In patients with pheochromocytoma, supraventricular
tachycardia occurs more often than ventricular arrhythmia
(11). However, ventricular tachycardia, including “torsades
de pointes’’, or rarely ventricular fibrillation has also been
described (12). The ischemia-appearing ECG changes make
the diagnosis of MI confounding (13). ECG abnormalities
like this may result from stimulation of the myocardium by
excessively high catecholamines levels, are transient, and
usually turn to normal after the removal of the tumor, which
suggests a toxic myocarditis rather than true transmural infarc-
tion (14, 15). ECG in this patient showed ST depression and
ST elevation, mimicking AMI, so that it was difficult to dif-
ferentiate between obstructive and nonobstructive coronary
lesion. We found normal coronary arteries on angiogram and
increased LV wall thickness (interventricular septal wall/pos-
terior wall, 16/15 mm) on echocardiography, which suggest-
ed catecholamine-induced cardiomyopathy associated with
pheochromocytoma.
Acute shock in this patient may be due to several possible
causes. First, acute spontaneous hemorrhage into the tumor
led to a massive release of catecholamines, which was proven
on pathology. Patients with a pheochromocytoma crisis caused
by spontaneous tumor necrosis or hemorrhage are exceeding-
ly rare but their presentation can be very severe (4). Second,
the clinical course of acute pulmonary edema and subsequent
cardiogenic shock can be explained by the severe diffuse myocar-
dial impairment present. Third reason for severe hypotension
might be the severely reduced blood volume.
From the recovery of cardiac function from severe left ven-
tricular dysfunction after removal of the tumor, it was the indi-
rect evidences that the heart had exposed to long-standing high
blood pressure. Hemorrhagic necrosis of the tumor led to a
massive release of catecholamines, which resulted in the patient’s
initial hypertension and subsequent cardiogenic shock (16).
There is no reliable, controlled data regarding the treatment
of adrenergic shock so far. Empiric supportive therapy counts
on general principles of therapy in shock. In the literature, early
detection and supportive care should be combined with treat-
ment of underlying disease to prevent the development of
irreversible multiorgan failure. Preoperative preparation with
volume replacement and alpha-adrenergic blockades (usual-
ly prazocin or phenoxylbenzamine) have accounted for the
most significant reductions in perioperative mortality (17).
Several preliminary clinical reports have suggested that
extracorporeal circulatory resuscitation can aid in the resus-
citation of patients with cardiopulmonary arrest regardless of
causes (18, 19). We found only one report of successful com-
bination of IABP and ECMO in management of acute myoc-
arditis (20). At present, IABP, ECMO, and ventricular assist
device (VAD) are available as extracorporeal support systems.
IABP is convenient to be applied but can only provide limit-
ed additional CO, which usually is not adequate for all criti-
cal situations. VAD implantation is expensive and time-con-
suming, and not always available for some patients group.
Besides, it also requires cardiopulmonary bypass for VAD
setup and removal (19). In case of IABP failure supporting the
patient, ECMO immediately provides adequate perfusion to
all organs irrespective of lung condition. It can be started
within 30 min at bedside and can take over the functions of
both ventricles and lungs. Furthermore, it can support the
failing heart for long term as needed and is easy to be remov-
ed at bedside in the intensive care unit. It also allows several
hours or days to try weaning ECMO if the bridging tube is
added to the circuit. It is reasonable to choose ECMO to treat
cardiomyopathy with shock that can usually improve with-
in 1 or 2 weeks (19). Catastrophic shock can be completely
reversible without leading to further damage after its recov-
ery from the acute phase, if ECMO can be provided in time
and long enough for the recovery of myocardium.
We conclude that a catecholamine-induced cardiomyopa-
thy in patients with a pheochromocytoma seems to be com-
pletely reversible and potentially cured by timely adequate
treatment. If not, an acute catecholamine crisis may be fatal.
Thus, if acute cardiogenic shock in patients with a pheochro-
mocytoma is unresponsive despite intensive medical treat-
ment, immediate mechanical support using IABP and PCPS
(percutaneous cardiopulmonary support) should be considered
as a very useful therapeutic choice alongside the classic ther-
apy of  - and  -adrenergic antagonist. Laparoscopic adrenalec-
tomy has become the procedure of choice for most patients,354 I.-W. Suh, C.W. Lee, Y.-H. Kim, et al.
with open adrenalectomy generally reserved for large tumors
or those most likely to be malignant (21).
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